Acceptability, effectiveness, and cost-effectiveness of internet-based exposure treatment for irritable bowel syndrome in a clinical sample: a randomized controlled trial

Brjánn Ljótsson, Gerhard Andersson, Erik Andersson, Erik Hedman, Perjohan Lindfors, Sergej Andréewitch, Christian Rück, Nils Lindefors, Brjánn Ljótsson, Gerhard Andersson, Erik Andersson, Erik Hedman, Perjohan Lindfors, Sergej Andréewitch, Christian Rück, Nils Lindefors

Abstract

Background: Internet-based cognitive behavior therapy (ICBT) has shown promising effects in the treatment of irritable bowel syndrome (IBS). However, to date no study has used a design where participants have been sampled solely from a clinical population. We aimed to investigate the acceptability, effectiveness, and cost-effectiveness of ICBT for IBS using a consecutively recruited sample from a gastroenterological clinic.

Methods: Sixty-one patients were randomized to 10 weeks of ICBT (n = 30) or a waiting list control (n = 31). The ICBT was guided by an online therapist and emphasized acceptance of symptoms through exposure and mindfulness training. Severity of IBS symptoms was measured with the Gastrointestinal symptom rating scale--IBS version (GSRS-IBS). Patients in both groups were assessed at pre- and post-treatment while only the ICBT group was assessed 12 months after treatment completion. Health economic data were also gathered at all assessment points and analyzed using bootstrap sampling.

Results: Fifty of 61 patients (82%) completed the post-treatment assessment and 20 of 30 patients (67%) in the ICBT group were assessed at 12-month follow-up. The ICBT group demonstrated significantly (p < .001) larger improvements on the IBS-related outcome scales than the waiting list group. The between group effect size on GSRS-IBS was Cohen's d = 0.77 (95% CI: 0.19-1.34). Similar effects were noted on measures of quality of life and IBS-related fear and avoidance behaviors. Improvements in the ICBT group were maintained at 12-month follow-up. The ICBT condition was found to be more cost-effective than the waiting list, with an 87% chance of leading to reduced societal costs combined with clinical effectiveness. The cost-effectiveness was sustained over the 12-month period.

Conclusions: ICBT proved to be a cost-effective treatment when delivered to a sample recruited from a gastroenterological clinic. However, many of the included patients dropped out of the study and the overall treatment effects were smaller than previous studies with referred and self-referred samples. ICBT may therefore be acceptable and effective for only a subset of clinical patients. Study dropout seemed to be associated with severe symptoms and large impairment. Objective and empirically validated criteria to select which patients to offer ICBT should be developed.

Trial registration: ClinicalTrials.gov: NCT00844961.

Figures

Figure 1
Figure 1
Participant flow through the trial.
Figure 2
Figure 2
Cost-effectiveness plane.

References

    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. doi: 10.1053/j.gastro.2005.11.061.
    1. Halder SL, Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther. 2004;19(2):233–242. doi: 10.1111/j.0269-2813.2004.01807.x.
    1. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229–1239. doi: 10.1111/j.1572-0241.2007.01740.x. quiz 1240.
    1. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol. 2000;95(1):67–71. doi: 10.1111/j.1572-0241.2000.01735.x.
    1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E. et al.U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569–1580. doi: 10.1007/BF01303162.
    1. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology. 1995;109(6):1736–1741. doi: 10.1016/0016-5085(95)90738-6.
    1. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N. et al.Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770–1798. doi: 10.1136/gut.2007.119446.
    1. Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511. doi: 10.1053/gast.2002.32978.
    1. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008;358(16):1692–1699. doi: 10.1056/NEJMcp0801447.
    1. Hungin AP. Self-help interventions in irritable bowel syndrome. Gut. 2006;55(5):603–604. doi: 10.1136/gut.2005.075606.
    1. Andersson G. Using the Internet to provide cognitive behaviour therapy. Behav Res Ther. 2009;47(3):175–180. doi: 10.1016/j.brat.2009.01.010.
    1. Bergström J, Andersson G, Ljótsson B, Rück C, Andréewitch S, Karlsson A, Carlbring P, Andersson E, Lindefors N. Internet- versus group-administered cognitive behaviour therapy for panic disorder in a psychiatric setting: a randomised trial. BMC Psychiatry. 2010;10(1):54. doi: 10.1186/1471-244X-10-54.
    1. Hedman E, Andersson G, Ljótsson B, Andersson E, Rück C, Mörtberg E, Lindefors N. Internet-Based Cognitive Behavior Therapy vs. Cognitive Behavioral Group Therapy for Social Anxiety Disorder: A Randomized Controlled Non-inferiority Trial. PLoS ONE. 2011;6(3):e18001. doi: 10.1371/journal.pone.0018001.
    1. Ljótsson B, Falk L, Wibron Vesterlund A, Hedman E, Lindfors P, Rück C, Hursti T, Andréewitch S, Jansson L, Lindefors N. et al.Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome - a randomized controlled trial. Behav Res Ther. 2010;48(6):531–539. doi: 10.1016/j.brat.2010.03.003.
    1. Ljótsson B, Hedman E, Andersson E, Hesser H, Lindfors P, Hursti T, Rydh S, Rück C, Lindefors N, Andersson G. Internet-Delivered Exposure-Based Treatment vs. Stress Management for Irritable Bowel Syndrome: A Randomized Trial. Am J Gastroenterol. 2011;106(8):1481–1491. doi: 10.1038/ajg.2011.139.
    1. Ljótsson B, Hedman E, Lindfors P, Hursti T, Lindefors N, Andersson G, Rück C. Long-term follow up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome. Behav Res Ther. 2011;49:58–61. doi: 10.1016/j.brat.2010.10.006.
    1. Andersson E, Ljótsson B, Smit F, Paxling B, Hedman E, Lindefors N, Andersson G, Rück C. Cost-effectiveness of internet-based cognitive behavior therapy for Irritable Bowel Syndrome: Results from a randomized controlled trial. BMC Public Health. 2011;11(1):215. doi: 10.1186/1471-2458-11-215.
    1. Ljótsson B, Andréewitch S, Hedman E, Rück C, Andersson G, Lindefors N. Exposure and mindfulness based therapy for irritable bowel syndrome - An open pilot study. J Behav Ther Exp Psychiatry. 2010;41(3):185–190. doi: 10.1016/j.jbtep.2010.01.001.
    1. Moss-Morris R, McAlpine L, Didsbury LP, Spence MJ. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med. 2010;40(1):85–94. doi: 10.1017/S0033291709990195.
    1. Jarrett ME, Cain KC, Burr RL, Hertig VL, Rosen SN, Heitkemper MM. Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. Am J Gastroenterol. 2009;104(12):3004–3014. doi: 10.1038/ajg.2009.479.
    1. Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy for irritable bowel syndrome. Behav Res Ther. 2009;47:797–802. doi: 10.1016/j.brat.2009.05.002.
    1. Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Holroyd K. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6(8):899–906. doi: 10.1016/j.cgh.2008.03.004.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295–309.
    1. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med. 2007;69(1):89–98. doi: 10.1097/PSY.0b013e31802e2f24.
    1. Almy TP, Tulin M. Alterations in colonic function in man under stress; experimental production of changes simulating the irritable colon. Gastroenterology. 1947;8(5):616–626.
    1. Mogg K, Mathews A, Bird C, Macgregor-Morris R. Effects of stress and anxiety on the processing of threat stimuli. J Pers Soc Psychol. 1990;59(6):1230–1237.
    1. Hazlett-Stevens H, Craske MG, Mayer EA, Chang L, Naliboff BD. Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res. 2003;55(6):501–505. doi: 10.1016/S0022-3999(03)00019-9.
    1. Labus JS, Bolus R, Chang L, Wiklund I, Naesdal J, Mayer EA, Naliboff BD. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004;20(1):89–97. doi: 10.1111/j.1365-2036.2004.02007.x.
    1. Jerndal P, Ringstrom G, Agerforz P, Karpefors M, Akkermans LM, Bayati A, Simren M. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil. 2010;22(6):646–e179. doi: 10.1111/j.1365-2982.2010.01493.x.
    1. Reme SE, Darnley S, Kennedy T, Chalder T. The development of the irritable bowel syndrome-behavioral responses questionnaire. J Psychosom Res. 2010;69(3):319–325. doi: 10.1016/j.jpsychores.2010.01.025.
    1. Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. Behav Ther. 2004;35(4):639–665. doi: 10.1016/S0005-7894(04)80013-3.
    1. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol. 2003;98(10):2209–2218. doi: 10.1111/j.1572-0241.2003.07716.x.
    1. Craske MG, Wolitzky-Taylor KB, Labus J, Wu S, Frese M, Mayer EA, Naliboff BD. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther. 2011;49(6-7):413–421. doi: 10.1016/j.brat.2011.04.001.
    1. Hayes SC, Villatte M, Levin M, Hildebrandt M. Open, aware, and active: contextual approaches as an emerging trend in the behavioral and cognitive therapies. Annu Rev Clin Psychol. 2011;7:141–168. doi: 10.1146/annurev-clinpsy-032210-104449.
    1. Kearney DJ, McDermott K, Martinez M, Simpson TL. Association of participation in a mindfulness programme with bowel symptoms, gastrointestinal symptom-specific anxiety and quality of life. Alimentary Pharmacology & Therapeutics. 2011.
    1. Gaylord SA, Palsson OS, Garland EL, Faurot KR, Coble RS, Mann JD, Frey W, Leniek K, Whitehead WE. Mindfulness Training Reduces the Severity of Irritable Bowel Syndrome in Women: Results of a Randomized Controlled Trial. Am J Gastroenterol. 2011.
    1. Chiesa A, Malinowski P. Mindfulness-based approaches: are they all the same? J Clin Psychol. 2011;67(4):404–424. doi: 10.1002/jclp.20776.
    1. Lynch TR, Chapman AL, Rosenthal MZ, Kuo JR, Linehan MM. Mechanisms of change in dialectical behavior therapy: theoretical and empirical observations. J Clin Psychol. 2006;62(4):459–480. doi: 10.1002/jclp.20243.
    1. Winzelberg AJ, Classen C, Alpers GW, Roberts H, Koopman C, Adams RE, Ernst H, Dev P, Taylor CB. Evaluation of an internet support group for women with primary breast cancer. Cancer. 2003;97(5):1164–1173. doi: 10.1002/cncr.11174.
    1. Hedman E, Ljótsson B, Rück C, Furmark T, Carlbring P, Lindefors N, Andersson G. Internet administration of self-report measures commonly used in research on social anxiety disorder: A psychometric evaluation. Computers in Human Behavior. 2010;26:736–740. doi: 10.1016/j.chb.2010.01.010.
    1. Ritter P, Lorig K, Laurent D, Matthews K. Internet versus mailed questionnaires: a randomized comparison. J Med Internet Res. 2004;6(3):e29. doi: 10.2196/jmir.6.3.e29.
    1. Wiklund IK, Fullerton S, Hawkey CJ, Jones RH, Longstreth GF, Mayer EA, Peacock RA, Wilson IK, Naesdal J. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003;38(9):947–954. doi: 10.1080/00365520310004209.
    1. Dimenäs E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30(11):1046–1052. doi: 10.3109/00365529509101605.
    1. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol. 2005;100(5):1174–1184. doi: 10.1111/j.1572-0241.2005.40674.x.
    1. Haakart-van Roijen L. Manual Trimbos/iMTA questionnaire for costs associated with psychiatric illness. Rotterdam: Institute for Medical Technology Assessment; 2002.
    1. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43(2):400–411. doi: 10.1023/A:1018831127942.
    1. Sheehan DV. The Anxiety Disease and How to Overcome It. New York: Charles Scribner and Sons; 1983. The Sheehan Disability Scales; p. 151.
    1. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93–105. doi: 10.2190/T8EM-C8YH-373N-1UWD.
    1. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
    1. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61(3):310–317. doi: 10.1001/archpsyc.61.3.310.
    1. Salim A, Mackinnon A, Christensen H, Griffiths K. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates. Psychiatry Res. 2008;160(3):335–345. doi: 10.1016/j.psychres.2007.08.005.
    1. Little RJA, Rubin DB. Statistical analysis with missing data. 2. Hoboken, N.J.: Wiley; 2002.
    1. Drummond MF, Sculpher MJ, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford University Press, USA; 2005.
    1. Smit F, Willemse G, Koopmanschap M, Onrust S, Cuijpers P, Beekman A. Cost-effectiveness of preventing depression in primary care patients: randomised trial. The British journal of psychiatry: the journal of mental science. 2006;188:330–336. doi: 10.1192/bjp.188.4.330.
    1. Organisation for economic co-operation and development: PPPs and exchange rates.
    1. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
    1. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. 1992;116(12 Pt 1):1009–1016.
    1. Reme SE, Stahl D, Kennedy T, Jones R, Darnley S, Chalder T. Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome. Psychol Med. 2011. pp. 1–11.
    1. Reme SE, Kennedy T, Jones R, Darnley S, Chalder T. Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care. J Psychosom Res. 2010;68(4):385–388. doi: 10.1016/j.jpsychores.2010.01.003.
    1. Jones MP, Bratten J, Keefer L. Quality of life in patients with inflammatory bowel disease and irritable bowel syndrome differs between subjects recruited from clinic or the internet. Am J Gastroenterol. 2007;102(10):2232–2237. doi: 10.1111/j.1572-0241.2007.01444.x.
    1. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol. 1996;91(2):277–283.
    1. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K. et al.Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19–31. doi: 10.1016/S0016-5085(03)00669-3.
    1. Blanchard EB, Lackner JM, Sanders K, Krasner S, Keefer L, Payne A, Gudleski GD, Katz L, Rowell D, Sykes M. et al.A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther. 2007;45(4):633–648. doi: 10.1016/j.brat.2006.07.003.
    1. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124(2):303–317. doi: 10.1053/gast.2003.50055.
    1. Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE. 2010;5(12):e15591. doi: 10.1371/journal.pone.0015591.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever